Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/30329% above fair value
$58.65+0.77 (+1.33%)
Close on Nov 18, 2026Market cap $3.00BP/E 139.6Yield –
Vericel gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Vericel's gross profit for the twelve months ending Jun 30, 2026 was $228.38M, up 24.8% year over year. For fiscal 2025 it was $205.60M, up 19.5% from the year before. Over ten years it grew 23.6% a year on average. The highest annual figure on record is $205.60M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.60M | +19.5% |
| FY2024 | Dec 31, 2024 | $172.11M | +26.9% |
| FY2023 | Dec 31, 2023 | $135.58M | +23.5% |
| FY2022 | Dec 31, 2022 | $109.79M | +3.5% |
| FY2021 | Dec 31, 2021 | $106.03M | +25.9% |
| FY2020 | Dec 31, 2020 | $84.23M | +4.9% |
| FY2019 | Dec 31, 2019 | $80.28M | +36.8% |
| FY2018 | Dec 31, 2018 | $58.70M | +74.8% |
| FY2017 | Dec 31, 2017 | $33.57M | +28.7% |
| FY2016 | Dec 31, 2016 | $26.08M | +5.6% |
| FY2015 | Dec 31, 2015 | $24.70M | +114.7% |
| FY2014 | Dec 31, 2014 | $11.50M | +76586.7% |
| FY2013 | Dec 31, 2013 | $15.00K | 0.0% |
| FY2012 | Dec 31, 2012 | $15.00K | -72.7% |
| FY2010 | Jun 30, 2010 | $55.00K | -21.4% |
| FY2009 | Jun 30, 2009 | $70.00K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $56.40M | +21.0% |
| Q1 FY2026 | Mar 31, 2026 | $49.27M | +35.8% |
| Q4 FY2025 | Dec 31, 2025 | $73.13M | +25.0% |
| Q3 FY2025 | Sep 30, 2025 | $49.59M | +19.0% |
| Q2 FY2025 | Jun 30, 2025 | $46.61M | +27.4% |
| Q1 FY2025 | Mar 31, 2025 | $36.27M | +2.6% |
| Q4 FY2024 | Dec 31, 2024 | $58.50M | +20.6% |
| Q3 FY2024 | Sep 30, 2024 | $41.65M | +36.1% |
| Q2 FY2024 | Jun 30, 2024 | $36.60M | +22.2% |
| Q1 FY2024 | Mar 31, 2024 | $35.35M | +33.3% |
| Q4 FY2023 | Dec 31, 2023 | $48.51M | +26.8% |
| Q3 FY2023 | Sep 30, 2023 | $30.61M | +21.3% |
| Q2 FY2023 | Jun 30, 2023 | $29.94M | +31.0% |
| Q1 FY2023 | Mar 31, 2023 | $26.52M | +13.1% |
| Q4 FY2022 | Dec 31, 2022 | $38.25M | +12.4% |
| Q3 FY2022 | Sep 30, 2022 | $25.23M | +14.2% |
| Q2 FY2022 | Jun 30, 2022 | $22.85M | -15.1% |
| Q1 FY2022 | Mar 31, 2022 | $23.45M | +2.0% |
| Q4 FY2021 | Dec 31, 2021 | $34.03M | +1.1% |
| Q3 FY2021 | Sep 30, 2021 | $22.10M | -1.7% |
| Q2 FY2021 | Jun 30, 2021 | $26.91M | +137.0% |
| Q1 FY2021 | Mar 31, 2021 | $22.99M | +37.2% |
| Q4 FY2020 | Dec 31, 2020 | $33.65M | +16.8% |
| Q3 FY2020 | Sep 30, 2020 | $22.47M | +6.1% |
| Q2 FY2020 | Jun 30, 2020 | $11.35M | -33.7% |
| Q1 FY2020 | Mar 31, 2020 | $16.76M | +27.2% |
| Q4 FY2019 | Dec 31, 2019 | $28.81M | +26.9% |
| Q3 FY2019 | Sep 30, 2019 | $21.18M | +47.6% |
| Q2 FY2019 | Jun 30, 2019 | $17.13M | +51.8% |
| Q1 FY2019 | Mar 31, 2019 | $13.17M | +27.1% |
| Q4 FY2018 | Dec 31, 2018 | $22.71M | +51.8% |
| Q3 FY2018 | Sep 30, 2018 | $14.35M | +102.8% |
| Q2 FY2018 | Jun 30, 2018 | $11.28M | +21.6% |
| Q1 FY2018 | Mar 31, 2018 | $10.36M | +360.1% |
| Q4 FY2017 | Dec 31, 2017 | $14.96M | 0.0% |
| Q3 FY2017 | Sep 30, 2017 | $7.07M | +73.7% |
| Q2 FY2017 | Jun 30, 2017 | $9.28M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.25M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.96M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.07M | – |
See a number that looks wrong?